Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a phone app stop deadly clots from coming back?

NCT ID NCT06382038

Disease control Sponsor: Navy General Hospital, Beijing Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 09, 2026 · Last updated Sep 10, 2026 · Updated 1 time

Summary

Researchers are testing a smartphone app designed to support patients after a pulmonary thromboembolism, a blood clot in the lungs. The app sends education and alerts tailored to each patient's clot and bleeding risk, and lets thrombosis doctors reach out during follow-up. The trial enrolls about 3,000 adults who have had a pulmonary thromboembolism and compares usual care with app-supported care. It tracks clot events, major bleeding, repeat hospital stays, and death over two years to see whether the app improves long-term outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a mobile app that sends tailored clot education and alerts to patients and doctors
What this could lead to
If the app helps, it could give patients with pulmonary thromboembolism a low-cost way to stay on track after leaving the hospital and reach clot specialists in areas with few of them.
What could go wrong
Phone-based support depends on patients using the app and on doctors acting on alerts, so benefits may fade in real life. The trial measures clot events over two years, and any effect on death or major bleeding may take longer to show.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 2,972 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2026

Expected to finish

Sep 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Inpatients aged ≥18 years; * PTE confirmed through imaging examinations, meeting at least one of the following criteria: a.Newly diagnosed PTE during the current hospitalization; b. Prior PTE with imaging evidence of residual thrombus. * Signed informed consent. Exclusion Criteria: * Previous PTE combined with CTEPH; * Mental retardation or a combination of other serious illnesses that make them incapable of living on their own; * Inability to use smartphones, computer tablets and other smart devices; * Being pregnant or breastfeeding; * Have participated in similar trials or are undergoing other clinical trials.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Digital health are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pulmonary embolism venous thromboembolism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Digital health Pulmonary thromboembolisms Venous thromboembolism

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Sixth Medical Center of Chinese PLA General Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100048, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.